1,853 material Form 8-K filings that 1,500 companies we cover made with the SEC in September 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
ONE Nuclear Energy completed its business combination with Hennessy Capital Investment Corp. VII (HVII) on September 23, 2026, and is no longer a shell company. The unaudited June 30, 2026 financials show a six-month net loss of $1,802,923, a working capital deficit of $2,736,205, and management's conclusion that substantial doubt exists about the company's ability to continue as a going concern, which matters to shareholders given the company's limited cash and reliance on financing.
Business combination with HVII consummated September 23, 2026; aggregate consideration of $1.0 billion payable to ONE Nuclear's equityholders in newly issued common stock
Net loss of $1,802,923 for the six months ended June 30, 2026; cash of $2,588 at June 30, 2026
Management determined substantial doubt exists about the company's ability to continue as a going concern
B. Riley fee of $12.0 million ($4.0 million in stock, $8.0 million in cash after closing); B. Riley note maturity extended to December 31, 2026
Stockholders of Apollo Commercial Real Estate Finance, Inc. approved the company's dissolution, the liquidation of its assets and the winding up of its business at a special meeting held September 29, 2026. The same day, the company and its manager signed a Termination Agreement to end the management agreement, which takes effect when Maryland accepts the articles of dissolution.
Dissolution proposal approved: 72,217,727 votes for, 799,088 against, 439,400 abstain
Advisory vote on executive compensation tied to the liquidation approved: 68,240,751 for, 4,229,423 against, 986,035 abstain
Manager waived any termination fee; the company agreed to pay accrued, unpaid management compensation and reimbursable expenses
Shares represented at the meeting were approximately 57.1% of issued and outstanding common stock entitled to vote
Aterian disclosed that David E. Lazar sold his Series AA and Series AAA preferred stake to several purchasers on September 25, 2026, for an aggregate $12,000,000. After the sale Lazar holds about 3.1% of common stock, and the company says no single person or group has acquired control. The filing also reports that director Avraham Ben-Tzvi resigned and William H. Crampton joined the board, and that a $0.9936-per-CVR cash payment is due on or about October 2, 2026.
On September 25, 2026, Lazar sold all rights in 706,100 Series AA and 1,750,000 Series AAA preferred shares for $12,000,000 in aggregate, after the preferred converted into 241,861,970 common shares.
No purchaser holds more than 9.99% of fully diluted common stock, and the company says the purchasers acted independently.
William H. Crampton was appointed to the board on September 25, 2026, and to the Audit and Compensation Committees; Avraham Ben-Tzvi resigned effective September 25, 2026.
Lazar received a $150,000 retention bonus as CEO and Interim CFO, paid in two $75,000 installments; CVR holders are due approximately $0.9936 per CVR on or about October 2, 2026.
MongoDB's Board of Directors authorized an additional $1.0 billion in share repurchases on September 25, 2026, bringing the aggregate authorized amount under its existing program to $2.0 billion. The company also held an Investor Day on September 29, 2026, where leadership discussed growth strategy while an interim CEO leads a pending leadership transition.
Board authorized an additional $1.0 billion in repurchases on September 25, 2026, for an aggregate $2.0 billion under the existing program.
$1,353,700,000 remains available for future repurchases as of the filing date.
Repurchases may be made in open market or privately negotiated transactions, and the company is not obligated to buy any particular amount.
Investor Day on September 29, 2026 covered strategy, and the presentation references a recently announced leadership transition led by interim CEO Dev Ittycheria.
Northern Trust Chief Financial Officer David W. Fox, Jr. told the company on September 28, 2026 that he plans to retire on or around March 31, 2027. The company said it will conduct a comprehensive internal and external search for his successor, and Fox is expected to keep leading Finance during the transition.
Fox informed the company on September 28, 2026 of his plan to retire, effective on or around March 31, 2027.
Fox intends to remain in his role through the end of the first quarter of 2027 to support an orderly transition.
The company plans a comprehensive internal and external search for its next Chief Financial Officer.
Fox joined Northern Trust in 2012 and previously spent more than 25 years at JPMorgan.
Talen's board named President Terry Nutt as chief executive effective January 1, 2027, succeeding Mac McFarland, who retires March 1, 2027. The same day, Talen entered $1.5 billion of accelerated share repurchase agreements, funded by selling about $1.5 billion of future PJM capacity revenues, and raised its remaining buyback authorization to $3.0 billion. For shareholders, the buyback reduces the share count, but the company says its adjusted free cash flow forecast for 2H 2026 through 2028 falls from about $4 billion to about $2.8 billion after the capacity sale.
Terry Nutt becomes CEO and joins the board on January 1, 2027; his base salary is set at $1,200,000, with a target bonus of 135% of base and a long-term incentive target of 700% of base.
Mac McFarland serves as Senior Advisor from January 1, 2027 until his retirement on March 1, 2027, and will receive $100,000 for those services.
The ASRs with Goldman Sachs & Co. LLC and Banco Santander cost $1.5 billion, with about 4.0 million shares initially received; the company expects them to be completed by the end of the first quarter of 2027 and says they would repurchase m
The capacity monetization covers PJM 2027/2028 and 2028/2029 delivery years, with Citi, at SOFR plus 200 basis points; the company targets net leverage of 3.5x by the second half of 2027.
Harvard Ave Acquisition Corporation, a blank check company (SPAC) listed on Nasdaq as HAVA, signed a business combination agreement on September 25, 2026 with OAG International Ltd, a provider of pipeline construction and integrity services. Under the deal, HAVA and OAG would each become wholly-owned subsidiaries of a newly formed holding company, PubCo, and HAVA shareholders would receive PubCo ordinary shares. The deal is subject to shareholder and regulatory approvals, and the filing states there is no assurance it will be completed.
Total merger consideration is $300 million, based on OAG's valuation after an OAG restructuring
HAVA and OAG must use reasonable best efforts to identify $30 million of equity financing within nine months after the second closing
Closing requires HAVA and OAG shareholder approval, a minimum $10 million of trust account cash net of redemptions and transaction expenses, and Nasdaq listing approval for PubCo
PubCo ordinary shares are expected to be listed on Nasdaq after closing
Concentrix reported fiscal third-quarter 2026 revenue of $2,453.7 million, down 1.2% from a year earlier, and a GAAP net loss of $988.1 million, or $(16.24) per diluted share, driven by a non-cash $1,050.0 million goodwill impairment. Excluding non-GAAP items, diluted EPS rose 5.0% to $2.92, and the company raised its quarterly dividend to $0.37 per share. The company guided fourth-quarter non-GAAP diluted EPS to $2.86 to $2.98 and full-year 2026 non-GAAP diluted EPS to $10.97 to $11.09.
Revenue was $2,453.7 million, down 1.2% as reported and down 0.5% in constant currency
GAAP operating loss of $(910.3) million and net loss of $(988.1) million include a $1,050.0 million goodwill impairment
Non-GAAP operating income rose 1.3% to $309.0 million and non-GAAP net income rose 1.8% to $186.5 million
Quarterly dividend raised to $0.37 from $0.36, payable November 3, 2026; no shares repurchased in the quarter, with $396.6 million authorization remaining
Fox Factory Holding Corp. completed the sale of Wheelhouse Holdings, parent of baseball bat maker Marucci Sports, to Squared Up Holdings, an investor group led by Marucci senior management, on September 25, 2026. The Company received $200 million in cash, which it used to reduce borrowings under its credit facility, plus a $25 million subordinated note due December 31, 2026. The unaudited pro forma financial information filed with the 8-K shows a $120.1 million loss on the disposal, which weighs on shareholders even as it reduces debt.
Enterprise value of $225 million, paid as $200 million in cash and a $25 million subordinated convertible note
Note matures December 31, 2026; if unpaid, principal increases by $2.5 million and interest rises to 10% per year
Pro forma loss on disposal of $120.1 million and approximately $7.5 million in transaction costs
Pro forma six-month net sales fell to $647.6 million from $726.8 million historical
Larimar Therapeutics appointed John B. Harlow, Jr. as President and Chief Operating Officer effective September 29, 2026, under an employment agreement with a $560,000 base salary and a 40% target annual bonus. He previously served as Chief Commercial Officer at Esperion Therapeutics from November 2025 to September 2026, and the filing describes a new senior operating role for the company.
Appointment effective September 29, 2026, as President and Chief Operating Officer
Base salary of $560,000 per year, a $35,000 cash signing bonus, and a target annual bonus of 40% of base salary
Inducement grants include an option on 800,000 shares and restricted stock units covering 50,000 shares, vesting over multiple years
Severance of nine months of base salary and COBRA coverage, or twelve months of salary plus target bonus and COBRA if terminated within one year after a change in control
Workday reiterated its fiscal 2027 third-quarter and full-year guidance from August 27, 2026, except for GAAP operating margin, which it now expects to be roughly 20 to 21 percentage points below non-GAAP margin in the third quarter and about 19 points below for the full year. The company is reducing about 2.5% of its workforce, mainly in Product and Technology, and reducing leased office space, with charges of $65 million to $80 million that shareholders will see in GAAP results.
Reorganizations announced September 29, 2026 include a reduction of about 2.5% of current workforce, mainly in Product and Technology.
Charges of $65 million to $80 million: about $55 million to $70 million in fiscal Q3 and $10 million in fiscal Q4 2027.
Charges include $40 million to $55 million in cash severance and benefit costs, about $10 million in stock-based compensation, and about $15 million in office space impairment.
Employee actions are expected to be substantially complete by Q1 fiscal 2028; office actions by Q4 fiscal 2027.
Maison Solutions Inc. said on September 23, 2026 that Nasdaq notified it of noncompliance with Listing Rule 5250(c)(1) because its quarterly report for the quarter ended July 31, 2026 was not filed on time and its annual report for the fiscal year ended April 30, 2026 remains delinquent. The notice has no immediate effect on the listing, but the company must submit a compliance plan by October 19, 2026, and Nasdaq may grant an exception until February 9, 2027 if it accepts the plan.
Nasdaq letter received September 23, 2026 cites late Form 10-Q for the quarter ended July 31, 2026 and delinquent Form 10-K for the fiscal year ended April 30, 2026
Compliance plan due to Nasdaq by October 19, 2026, a deadline set in an earlier August 20, 2026 notice
If Nasdaq accepts the plan, the exception could run to February 9, 2027; if not, the company may appeal to a Nasdaq Hearings Panel
Class A common stock continues to trade on The Nasdaq Capital Market under the symbol MSS
Carnival reported record third-quarter 2026 results for the period ended August 31, with net income attributable to the company of $1.92 billion, up from $1.85 billion a year earlier, and revenue of $8.4 billion, up from $8.2 billion. The company said its full-year 2026 adjusted net income outlook improved by more than $150 million compared with June guidance, offsetting a $150 million impact from higher fuel prices.
Q3 net income attributable to Carnival was $1.92 billion versus $1.85 billion a year earlier; total revenues were $8.4 billion versus $8.2 billion.
Diluted EPS was $1.40 versus $1.33 a year earlier; adjusted EPS was $1.43, in line with the prior year.
Full-year 2026 adjusted net income is now expected to improve by more than $150 million versus June guidance, overcoming a $150 million impact from increased fuel prices.
The company completed about $1.2 billion of share repurchases year to date and paid $618 million in dividends for the first nine months.
uniQure presented additional data from its ongoing Phase I/II studies of AMT-130 for Huntington's disease, comparing treated patients with updated external controls. The 36-month analysis of all 15 high-dose patients showed 80% slowing on cUHDRS (nominal p=0.005) and 67% on TFC (nominal p=0.011), and the company says the BLA submission was based on 36-month data. The 48-month primary cUHDRS result showed 44% slowing but did not reach statistical significance (p=0.144), and the company notes that missing data and survivor bias in the updated control may understate the treatment effect.
36-month analysis of 15 high-dose patients: 80% slowing of cUHDRS decline (nominal p=0.005) and 67% slowing of TFC decline (nominal p=0.011)
48-month analysis of 12 high-dose patients: 44% slowing on cUHDRS (p=0.144, not significant) and 61% slowing on TFC (nominal p=0.008)
Data missingness in the updated Enroll-HD B control reached 53% at Month 48; data cutoff was June 30, 2026
Company says the BLA was submitted on 36-month data, which the FDA said at a June 2026 Type B meeting would be acceptable under the accelerated approval pathway
CareCloud's Board appointed Bonnie Boyer, currently Assistant Chief Financial Officer, as Chief Financial Officer effective October 1, 2026, succeeding Norman Roth, who has served as Interim CFO for more than two years. Mr. Roth becomes Advisor to the Chief Executive Officer. The filing also sets out Ms. Boyer's employment terms, including a $300,000 base salary and a target bonus of 30% of base salary.
Bonnie Boyer, 39, joined CareCloud on July 9, 2026, as Assistant CFO and becomes CFO effective October 1, 2026.
Base salary of $300,000 with an annual target bonus equal to 30% of base salary.
Norman Roth, Interim CFO and Corporate Controller, transitions to Advisor to the CEO effective October 1, 2026.
Severance includes six months of base salary and COBRA premiums if terminated without cause; if terminated in connection with a change of control, salary continuation for at least 24 months.
Imunon, Inc. agreed on September 28, 2026 to exchange $1,200,000 of principal on its A-1 secured note held by Streeterville Capital, LLC for 120 shares of newly designated Series B Preferred Stock, reducing the note balance by the amount exchanged. The company also filed a certificate of designation creating 200 Series B shares with an 8% annual return and a 110% optional redemption price, which carries event-of-default terms that could raise the return by 15% a year.
Exchange covers $1,200,000 of A-1 Note principal plus accrued interest, for 120 Series B Preferred Shares at $10,000 per share.
Series B Preferred Stock has a $12,000 stated value, an 8% annual return, and is not convertible into common stock.
Company may redeem Series B shares at 110% of the applicable liquidation amount; an event of default would raise the return by 15% per year.
Series B holders have no voting rights except on matters that materially and adversely affect their rights or as required by law.
SurgePays received a Nasdaq letter granting an additional 180-day period, to March 22, 2027, to regain compliance with the $1.00 minimum bid price requirement. Nasdaq also said the company now meets the stockholders' equity requirement, but could face delisting if it fails to show compliance with continued listing criteria in its next periodic report.
Nasdaq granted an additional 180-calendar-day period, ending March 22, 2027, to regain the $1.00 minimum bid price.
The initial compliance period expired September 21, 2026, after Nasdaq first flagged the deficiency on March 23, 2026.
Nasdaq separately determined the company complies with the stockholders' equity requirement, addressing its March 18, 2026 letter.
If the company does not regain compliance by March 22, 2027, Nasdaq will issue a delisting notice; the company has said it may reverse split if necessary.
Atossa Therapeutics' board approved a plan to issue one contingent value right (CVR) for each common share, giving shareholders a share of proceeds if the company monetizes its first qualifying rare pediatric disease priority review voucher. No voucher has been awarded and no product candidate has been approved, so no CVR payment is assured.
Each CVR would entitle holders to 25% of net proceeds from a qualifying voucher monetization, capped at $50 million in aggregate payments.
Shareholders of record on a record date to be announced, and shares issued later, would receive one CVR per share.
CVRs would not trade separately and would expire if no qualifying voucher is awarded by December 31, 2036, unless the Board extends that date.
Atossa has previously reported disclosed voucher sales of $100 million to $220 million over the preceding 18–24 months, but past sales do not establish the value of any voucher it might receive.
Unicycive Therapeutics resubmitted its New Drug Application for oxylanthanum carbonate (OLC) on September 29, 2026, with chemistry and manufacturing data from a new third-party drug product vendor. The company expects FDA acceptance within 30 days and a new PDUFA date six months from resubmission, following a June 2026 Complete Response Letter. The company also appointed Meredith S. Manning as an independent director effective October 1, 2026.
NDA resubmitted September 29, 2026, including CMC data from a new third-party drug product manufacturing vendor and 12 months of OLC drug product stability data.
Company anticipates FDA acceptance within 30 days; new PDUFA date expected six months from resubmission.
June 2026 CRL cited the same third-party manufacturing deficiencies as the June 2025 CRL; the original vendor's FDA inspection had not occurred as of September 29, 2026.
Meredith S. Manning appointed independent director effective October 1, 2026; cash, equivalents and marketable securities were $61.4 million as of June 30, 2026.
SoundThinking agreed on September 28, 2026 to be acquired by Transom Capital Group through a tender offer for $8.00 per share in cash plus one non-transferable contingent value right worth up to $3.00 per share. The up-front price is a 46% premium to the September 28, 2026 closing price, and holders of about 33% of the outstanding shares have already agreed to tender, so the deal would give shareholders a cash exit if completed.
Up-front cash of $8.00 per share, plus a CVR paying up to $3.00 per share tied to 2027 revenue milestones for ShotSpotter and SafePointe
Implied enterprise value of about $114 million on up-front consideration, or about $159 million with the maximum CVR payment
Veradace Partners (about 16%) and Gary M. Lauder and affiliates (about 17%) agreed to tender their shares; the offer requires more than 50% of outstanding shares to be tendered
Closing is expected in the fourth quarter of 2026; the deal has no financing condition, and shares will stop trading on Nasdaq once completed
Invivyd reported topline results from the Phase 3 LIBERTY study of its investigational COVID-19 antibody VYD2311, which it says showed a safety and tolerability profile superior to an mRNA COVID-19 vaccine. The company also plans to submit a Biologics License Application to the FDA under the Accelerated Approval pathway, pending data from the ongoing DECLARATION pivotal study expected in October 2026. For shareholders, the results come from a 210-person study, and the regulatory path depends on DECLARATION data that have not yet been reported.
VYD2311 alone: 56.5% of subjects had a treatment-emergent adverse event, injection site reaction or hypersensitivity reaction over 6 days, versus 91.4% in the mRNA vaccine arm (P<0.0001).
VYD2311 combined with the mRNA vaccine: 78.9% versus 91.4% on the same measure, with P=0.057 for that comparison.
DECLARATION topline safety and immunogenicity data are expected in October 2026; that study enrolls approximately 2,400 participants.
LIBERTY enrolled 210 healthy adults aged 18 to 49, randomized 1:1:1 across three arms.
1-800-FLOWERS.COM signed an asset purchase agreement on September 26, 2026, to sell its Personalization Mall, Things Remembered and Personalization Universe businesses to PlanetArt, LLC for $45.0 million in cash, subject to working capital and other adjustments. The company said the deal is targeted to close within the coming weeks and that its fiscal 2027 guidance did not include the transaction, with an update expected alongside its first quarter fiscal 2027 earnings release.
Purchase price is $45.0 million in cash, subject to working capital and other adjustments
Agreement signed September 26, 2026; announced in a press release dated September 29, 2026
Closing is subject to customary conditions and specified third party consents; a commercial agreement and transition services agreement are contemplated
Fiscal 2027 guidance given September 10, 2026 excludes the transaction; update expected with first quarter fiscal 2027 results
BeyondSpring agreed to sell its Chinese holding subsidiary, BeyondSpring Ltd., to Biolin Investment Limited. In exchange, Biolin's non-cash consideration is to fund the China portion of the Phase 3 DUBLIN-4 trial, and no cash is payable at closing. The company also set up an at-the-market program to sell up to 9,200,000 ordinary shares, which could dilute existing shareholders, and announced FDA Fast Track designation for Plinabulin.
Sale of BeyondSpring Ltd. to Biolin under a Share Purchase and Collaboration Agreement dated September 28, 2026; no cash paid to the company at closing
If Bulin misses the Target Enrollment within three years after closing, the investor must return part or all of the equity interests, with 100% returned if the shortfall is 90% or greater
ATM program with Citizens JMP Securities for up to 9,200,000 ordinary shares, with commission of up to 3.0% of gross proceeds
FDA granted Fast Track designation to Plinabulin and docetaxel for post-ICI non-squamous NSCLC; DUBLIN-4 plans approximately 442 patients with an interim analysis at 221 PFS events
Aldeyra Therapeutics said it intends to submit a Formal Dispute Resolution Request to the FDA, appealing the March 16, 2026 Complete Response Letter that denied approval of reproxalap for dry eye disease. The company also extended its projected operational cash runway into 2029, based on $45.1 million in cash and cash equivalents as of June 30, 2026. The appeal's outcome and timing remain uncertain, and the filing states that the FDRR submission and meeting with the Office of New Drugs are expected in the fourth quarter of 2026.
Intends to submit an FDRR to the FDA's Office of New Drugs, appealing the March 16, 2026 Complete Response Letter for reproxalap
FDRR submission and a meeting with the Office of New Drugs are expected in the fourth quarter of 2026
Cash and cash equivalents were $45.1 million as of June 30, 2026; operational cash runway extended into 2029
Immix Biopharma said an interim update from its Phase 2 NEXICART-2 trial shows an 89% (40/45) complete response rate across all 45 enrolled relapsed/refractory AL Amyloidosis patients, as assessed by an independent review committee. The company said the final readout and BLA submission are planned for mid-2027, so the data remain interim and the therapy has not been approved.
Complete response rate of 89% (40/45) across all 45 enrolled patients, per an independent review committee
All 25 new patients are in complete response or MRD-negative (21 in CR, 4 MRD-negative)
Four MRD-negative patients still pending; the company says this could raise the CR rate to up to 98% (44/45)
Final readout and BLA submission planned for mid-2027; company reported no neurotoxicity or enterocolitis to date
Westlake approved a plan to cease operations at its 165,000-metric-ton-a-year PVC plant in Cologne, Germany, with closure expected in the first quarter of 2027 and about 120 jobs affected. The company expects total pre-tax charges of about $205 million, and said it expects sequentially lower financial performance in the third quarter of 2026 than in the second quarter.
Total pre-tax closure charges of about $205 million: about $105 million non-cash and about $100 million cash
About $110 million of the charges expected to be recorded in 2026, with the remainder in 2027
Production to shift to other German sites, including the recently acquired Wilhelmshaven facility
Westlake expects sequentially lower third-quarter 2026 financial performance versus the second quarter
Stewards completed its acquisition of Envy Pompano Beach, a 214-unit apartment and mixed-use property in Florida, on September 23, 2026, with a contractual price of $90.0 million paid partly in 14,263,025 newly issued common shares. The company must make $3.0 million monthly cash payments to sellers from October 2026 through April 2027, while 7,000,000 escrowed shares are cancelled over that period, and it took on a $47.7 million mortgage loan, which adds share dilution and cash obligations for shareholders.
Closed September 23, 2026; contractual price of $90.0 million, including 14,263,025 shares at a $3.00 contractual value per share and $44,557,435.93 of refinanced property debt
7,000,000 shares placed in escrow; $3.0 million cash payments due monthly from October 5, 2026 through April 5, 2027, with 1,000,000 escrowed shares cancelled per payment
$47.7 million LoanCore mortgage loan at one-month Term SOFR (3.35% floor) plus 3.60%, interest-only, maturing October 9, 2028
If shares are delisted from Nasdaq and not relisted within 120 days, the company must pay sellers $5.5 million per payment, subject to a $33.0 million aggregate cap
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.